CLAIMS

1. Use of a liposome preparation containing a population of liposomes containing a CD1d ligand compound in the manufacture of a medicament for the prevention or treatment of graft-versus-host disease, wherein the average particle size of the population of liposomes is 90 to 110 nm, and the polydispersity index of the particle size distribution is 0.2 or less.

2. The use according to claim 1, wherein the average particle size is 92.9 to 101.0 nm.

3. The use according to claim 1 or 2, wherein the polydispersity index of the particle size distribution is 0.133 or less.

4. The use according to any one of claims 1 to 3, wherein the number of liposomes having a particle size of less than 50 nm is 10% or less of the total population of liposomes.

5. The use according to any one of claims 1 to 4, wherein the number of liposomes with a particle size of more than 450 nm is 10% or less of the total population of liposomes.

6. The use according to any one of claims 1 to 5, wherein the average particle size is maintained at 90 to 110 nm for at least 1 month under the conditions of a temperature of 25°C and a relative humidity of 60% RH.

7. The use according to any one of claims 1 to 6, wherein the CD1d ligand compound is α-galactosylceramide.

8. The use according to claim 7, wherein the α-galactosylceramide is (2S,3S,4R)-1-o-(α-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol.

9. The use according to any one of claims 1 to 8, wherein the population of liposomes is contained as a liposome suspension.

10. The use according to claim 9, wherein the pH of the liposome suspension is 5.8 to 6.8.

11. The use according to any one of claims 1 to 8, wherein the population of liposomes is contained as a lyophilized product.

12. The use according to any one of claims 1 to 11, which is for injection administration.

13. The use according to any one of claims 1 to claim 12, wherein the graft-versus-host disease is caused by allogeneic hematopoietic stem cell transplantation.